Immune system receptors and cells

Immune system receptors and cells refers to the vast network of biological structures and processes that protect an organism against disease [1]. This category includes various cell types such as lymphocytes (T-cells, B-cells, NK cells) and myeloid cells (monocytes, macrophages, neutrophils), as well as the specific receptors they express to sense the environment, such as T-cell receptors (TCR), B-cell receptors (BCR), and Toll-like receptors (TLR) [2][3]. In the context of drug discovery, this term is considered too broad to be a single therapeutic target; rather, it represents a physiological system containing thousands of potential targets [4]. Therapeutic intervention in this system typically involves modulating specific pathways to either suppress an overactive immune response (as in autoimmune diseases) or stimulate a dormant one (as in oncology) [5]. Common pharmacological strategies include the use of monoclonal antibodies to neutralize cytokines or block checkpoint receptors, and small molecules to inhibit intracellular signaling kinases like JAK or BTK [6]. Dysregulation of these receptors and cells is central to the pathogenesis of autoimmune disorders, chronic inflammation, and cancer. Consequently, many modern therapies are designed to either enhance or suppress specific immune pathways to treat these conditions.

Other names

Immune system componentsLeukocytes and receptorsImmunological targets

Drugs targeting these components act through diverse mechanisms including immune checkpoint inhibition, cytokine neutralization, lymphocyte depletion, and signal transduction modulation.